Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome- and immune-targeted drugs that have transformed the outcomes of some malignancies1. Tumor complexity and heterogeneity suggest that the ‘precision medicine’ paradigm of cancer therapy requires treatment to be personalized to the individual patient2–6. To date, precision oncology trials have been based on molecular matching with predetermined...